Your browser doesn't support javascript.
loading
Decreased Dolutegravir and Efavirenz Concentrations With Preserved Virological Suppression in Patients With Tuberculosis and Human Immunodeficiency Virus Receiving High-Dose Rifampicin.
Sekaggya-Wiltshire, Christine; Nabisere, Ruth; Musaazi, Joseph; Otaalo, Brian; Aber, Florence; Alinaitwe, Lucy; Nampala, Juliet; Najjemba, Letisha; Buzibye, Allan; Omali, Denis; Gausi, Kamunkhwala; Kengo, Allan; Lamorde, Mohammed; Aarnoutse, Rob; Denti, Paolo; Dooley, Kelly E; Sloan, Derek J.
Afiliação
  • Sekaggya-Wiltshire C; Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda.
  • Nabisere R; Department of Medicine, Mulago National Referral Hospital, Kampala, Uganda.
  • Musaazi J; Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda.
  • Otaalo B; Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda.
  • Aber F; Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda.
  • Alinaitwe L; Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda.
  • Nampala J; Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda.
  • Najjemba L; Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda.
  • Buzibye A; Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda.
  • Omali D; Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda.
  • Gausi K; Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda.
  • Kengo A; Department of Medicine, Division of Clinical Pharmacology, University of Cape Town, Cape Town, South Africa.
  • Lamorde M; Department of Medicine, Division of Clinical Pharmacology, University of Cape Town, Cape Town, South Africa.
  • Aarnoutse R; Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda.
  • Denti P; Department of Pharmacy and Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegene, The Netherlands.
  • Dooley KE; Department of Medicine, Division of Clinical Pharmacology, University of Cape Town, Cape Town, South Africa.
  • Sloan DJ; Department of Medicine, Division of Clinical Pharmacology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Clin Infect Dis ; 76(3): e910-e919, 2023 02 08.
Article em En | MEDLINE | ID: mdl-35861296
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 2_ODS3 / 3_ND Base de dados: MEDLINE Assunto principal: Tuberculose / Infecções por HIV / Fármacos Anti-HIV Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Revista: Clin Infect Dis Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 2_ODS3 / 3_ND Base de dados: MEDLINE Assunto principal: Tuberculose / Infecções por HIV / Fármacos Anti-HIV Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Revista: Clin Infect Dis Ano de publicação: 2023 Tipo de documento: Article